eGenesis

There is a barn in the American Midwest that looks more like a microchip fab than a farm. Air filtered. Staff gowned. Pigs raised pathogen-free behind biosecurity doors. Each animal carries dozens of deliberate edits to its genome. Each is, in the most literal sense, a work in progress toward a human organ. This is eGenesis.

Today eGenesis is a clinical-stage biotech with a kidney inside living people. In January 2025 a 67-year-old man named Tim Andrews received one of its engineered pig kidneys at Massachusetts General Hospital and walked away from dialysis. Months later he was still going - the longest-surviving recipient of a gene-edited animal organ on record. By that summer the FDA had cleared the company's lead candidate for a formal clinical trial. The pig organ had graduated from thought experiment to medicine under review.

It is a strange thing to build a company around. Most biotechs chase a molecule. eGenesis chases a whole organ, grown in another species, and bets the human immune system can be talked out of its oldest instinct - to destroy anything that isn't us.

01 / The ProblemThe math of the waiting list

Start with the number that haunts every transplant surgeon: in the United States alone, more than 100,000 people sit on the organ waiting list, the large majority of them waiting for a kidney. Many will wait years. Some will die first. The supply of human donor organs is, and always has been, a tragedy of scarcity - you cannot manufacture grief on schedule, and grief is where most donor organs come from.

For decades the obvious workaround - take an organ from an animal - was a dead end. Pig organs are biologically close enough to tempt surgeons and just different enough to kill the patient. The human body recognizes pig sugars instantly and attacks. Pig DNA carries ancient retroviruses no one wanted to introduce into a hospital. The gap between "almost works" and "works" was, for a long time, uncrossable.

02 / The BetTwo geneticists and a very long list of edits

In 2015, geneticist George Church - one of the architects of modern genome science - and his lab researcher Luhan Yang spun eGenesis out of Harvard's Wyss Institute. Their wager was specific: if you could edit not one gene but many at once, you could redesign a pig until its organs read as human-compatible. Remove the offending sugars. Insert human genes that calm the immune response and prevent clotting. Switch off every copy of those embedded retroviruses.

That last part had been considered nearly impossible. Yang's early work demonstrated inactivating dozens of porcine endogenous retroviruses across the genome in a single push - the kind of result that turns a skeptic's eyebrow. It was less a tweak than a rewrite, and it gave the company its founding credibility.

The leadership later passed to Michael Curtis, a drug-development veteran with 35-plus years across biopharma, who took the chief executive role to steer the company from elegant science toward the far less elegant world of regulators, trial protocols, and manufacturing at scale. Founders dream the molecule; someone has to file the paperwork.

03 / The ProductAn organ pipeline, not a pill

At the core sits the EGEN platform - the Genome Engineering and Production system that does the multiplex editing, then produces cloned, biosecure donor animals whose organs carry every change. Out of it come three programs, each aimed at a place where the donor shortage bites hardest.

EGEN-2784 is the lead: an engineered porcine kidney for end-stage kidney disease, now the basis of an FDA-cleared trial in dialysis-dependent patients age 50 and up. EGEN-5784 is the liver program, paired with OrganOx's cross-circulation system to keep patients in acute liver failure alive while the engineered organ does the work. A third program targets pediatric heart failure - a population with almost no donor options at all.

04 / The ProofPatients, dollars, and partners

Proof in this field is brutally concrete: a person, an organ, a clock. eGenesis has three patients who have received its kidney under Expanded Access, including the record-setting Tim Andrews and, in June 2025, a third recipient named Bill Stewart. The FDA's decision to allow a broader trial is its own kind of proof - regulators do not authorize first-in-human studies on hope alone.

The capital tells a parallel story. Funding climbed round over round, with the 2024 Series D drawing not just venture firms but strategic backers tied directly to the patient population - DaVita in dialysis, Fresenius Medical Care, Eisai, and others alongside Lux Capital, ARCH, Khosla, and Leaps by Bayer. Investors who supply the kidney-care ecosystem do not usually write checks unless they think the supply problem might actually move.

05 / The MissionOrgans on a schedule

"We believe in the power of innovation to save and transform lives," reads the company's own line - the sort of sentence every biotech keeps on the shelf. eGenesis earns it by being unusually literal about the goal: an engineered organ available when a patient needs it, rather than whenever tragedy supplies one. The mission is not to invent a new therapy class for its own sake. It is to make the waiting list shorter, and eventually to make it strange that a waiting list existed at all.

There are real questions left, and the company is candid that it is still in trials. Long-term organ survival, durability across many patients, the economics of producing organs under cleanroom biosecurity, and the public's comfort with animal-to-human transplant all remain open. None of these are solved by a press release. They are solved by patients, years, and data - the slow currency this field trades in.

06 / TomorrowWhy the barn matters

Return to that filtered, gowned, faintly surreal barn. For most of medical history, an organ was a thing you received only because someone else lost theirs. Scarcity was assumed - baked into the system, mourned but accepted. eGenesis is trying to break that assumption: to make a human-compatible organ something you can engineer, produce, and supply, the way you would any other critical medicine.

It has not won yet. Trials are running, not finished, and the honest version of this story ends with a question mark. But the barn now holds something that didn't exist a decade ago - organs designed, not donated, with patients walking around who are living proof the idea has weight. The waiting list is still long. For the first time, it has a credible reason to get shorter.

Dossier compiled from public sources · figures approximate where noted